

---

## **AcouSort continues its strategic collaboration with academia – delivers a unique AcouWash 2 system to Lund University**

**In the autumn of 2022, AcouSort received an order from Lund University for the development of a modified AcouWash 2 system, custom-designed to support the separation of circulating tumor cells (CTC) from white blood cells. The project will generate revenues of SEK 500,000 in 2023.**

The unique pre-focusing feature of the modified AcouWash 2 system enables high-precision separation and will be used to extract CTC from patient samples in a project at Lund University. The high-precision capability allows for a range of new applications within research and diagnostics, including the separation of CTC from white blood cells. The purpose of extracting CTC is to develop new methods to discover cancer at an early stage, which can be crucial for the survival of the patient.

*“The modified AcouWash 2 system that we now have delivered to Lund University is yet another example of our successful collaboration with academia. By working together with leading scientists, we continuously expand the space for what our technology can achieve,”* says AcouSort’s Commercial Director Agnes Michanek.

**For further information on AcouSort, please contact:**

Torsten Freltoft, CEO

Telephone: +45 2045 0854

E-mail: [torsten.freltoft@acousort.com](mailto:torsten.freltoft@acousort.com)

---

### **About AcouSort**

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company's Certified Adviser is Erik Penser Bank.